Comparative Pharmacology
Head-to-head clinical analysis: PENICILLIN G SODIUM versus UTICILLIN VK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENICILLIN G SODIUM versus UTICILLIN VK.
PENICILLIN G SODIUM vs UTICILLIN VK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Uticillin VK (penicillin V potassium) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) in the bacterial cytoplasmic membrane, thereby inhibiting transpeptidation and autolysin inhibition, leading to cell lysis and death.
2-4 million units intravenously every 4 hours for moderate to severe infections; up to 24 million units/day for severe infections (e.g., meningitis, endocarditis).
250-500 mg orally every 6-8 hours for 10 days for streptococcal pharyngitis; 250-500 mg orally every 6 hours for pneumococcal infections.
None Documented
None Documented
30-60 minutes in normal renal function; prolonged to 7-10 hours in anuria.
0.5-1.0 hour (prolonged in renal impairment; e.g., up to 10 hours in anuria)
Primarily renal (60-90% unchanged) via glomerular filtration and tubular secretion; minor biliary/fecal (<10%).
Renal: 70-80% unchanged via tubular secretion and glomerular filtration; biliary/fecal: minor (about 10%)
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic